Ipsen has completed its acquisition of Memo Therapeutics, which adds potravitug, an anti-BKPyV antibody, to its rare disease pipeline.
Ipsen announced July 22, 2026, that it has completed its
"With potravitug, we have the opportunity to add a promising first-in-class asset to our rare disease pipeline and address the significant clinical consequences of BK virus–associated nephropathy in kidney transplant recipients, where current standards of care can compromise transplant success and graft outcomes," said
Potravitug has been evaluated in the phase 2 SAFE KIDNEY II trial, which Ipsen describes as the largest placebo-controlled study conducted in this patient population, with additional analyses presented at international renal and transplant congresses.1
The phase 2 SAFE KIDNEY II trial enrolled 95 kidney transplant recipients with BKPyV reactivation across 22 US sites.2 By week 38, 24.4% of potravitug-treated patients achieved undetectable BKPyV-DNAemia versus 13.0% on placebo, and 40.3% achieved a greater than 2-log10 viral load reduction versus 24.7% on placebo.2
By week 20, biopsy-proven BKPyV-associated nephropathy (BKVAN) had declined from 51.2% to 31.6% in the potravitug arm, with no corresponding change in the placebo arm; Ipsen reported no treatment-related serious adverse events.2 The company has stated the totality of this evidence supports moving into a pivotal phase 2/3 trial later in 2026.2
BKPyV is a common virus most people first encounter in childhood and that typically remains dormant.1 In immunocompromised patients, including transplant recipients on anti-rejection therapy, the virus can reactivate; around 90% of kidney transplant recipients are BKPyV-seropositive, and roughly 30% show elevated blood BKPyV levels indicating reactivation within the first year post-transplant.1
BKVAN can raise the risk of graft loss and may require dialysis or re-transplantation.1 With no approved targeted therapy, clinical management instead centers on reducing immunosuppression to balance graft protection against viral control, which is a trade-off that itself elevates rejection risk.3
Potravitug is a monoclonal antibody directed against the BKPyV VP1 capsid protein, working by blocking viral attachment and cell entry to prevent infection of host cells and subsequent replication.2
The scale of the underlying patient population is substantial: more than 100,000 kidney transplants are performed worldwide each year, including over 28,000 in the United States, with more than 90,000 patients on the US waiting list.4
The acquisition adds potravitug to rare disease, one of Ipsen's three core therapeutic areas alongside oncology and neuroscience.1
Under deal terms disclosed when the agreement was signed, Memo Therapeutics shareholders received €200 million (US$228 million) upfront, with additional development, regulatory, and sales-based milestone payments that could bring total consideration to more than €700 million (US$799 million).2
Ipsen's July 22 completion announcement does not itself restate numeric trial results or deal terms. Those figures were disclosed when
As with any newly acquired late-stage asset, potravitug still requires further clinical development, including the planned pivotal trial, and regulatory review before it could reach patients.
